Drug Trial Radar · NCT02446899
Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
Last checked: Nov 20, 2026Latest source record: Jan 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
373
Actual
Start
Jul 9, 2015
Primary completion
Sep 27, 2018
Study completion Sep 27, 2018
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- PRA Health Sciences
- First posted
- May 18, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in adult participants with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).
Conditions
- Active Systemic Lupus Erythematosus
Interventions
AnifrolumabBiological
Intravenous infusion (IV)
PlaceboDrug
Intravenous infusion (IV)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52Time frame: Baseline; Week 52
Locations
113 sites in 15 countries. Site status is shown where the registry gives one.
Research Site
Covina, California
Research Site
Hemet, California
Research Site
Los Angeles, California
Research Site
San Leandro, California
Research Site
Torrance, California
Research Site
Upland, California
Research Site
Denver, Colorado
Research Site
Bridgeport, Connecticut
Research Site
Bridgeport, Connecticut
Research Site
Brandon, Florida
Research Site
Orlando, Florida
Research Site
Palm Harbor, Florida
Research Site
Tamarac, Florida
Research Site
Tampa, Florida
Research Site
Atlanta, Georgia
Research Site
Boston, Massachusetts
Research Site
Ann Arbor, Michigan
Research Site
Lincoln, Nebraska
Research Site
Las Cruces, New Mexico
Research Site
Brooklyn, New York
Research Site
New York, New York
Research Site
New York, New York
Research Site
New York, New York
Research Site
Greenville, North Carolina
Research Site
Oklahoma City, Oklahoma
Research Site
Duncansville, Pennsylvania
Research Site
Pittsburgh, Pennsylvania
Research Site
Memphis, Tennessee
Research Site
Dallas, Texas
Research Site
Houston, Texas
Research Site
Houston, Texas
Research Site
Stafford, Texas
Research Site
Arlington, Virginia
Research Site
Seattle, Washington
Research Site
Spokane, Washington
Research Site
Buenos Aires, Argentina
Research Site
Mendoza, Argentina
Research Site
Quilmes, Argentina
Research Site
Brussels, Belgium
Research Site
Leuven, Belgium
Showing 40 of 113 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.